Undecimal Bio

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Undecimal Bio - overview

Established

2025

Location

Tel Aviv, -, Israel

Primary Industry

Biotechnology

About

Based in Israel, Undecimal Bio, operates as a provider of RNA delivery technology for therapeutic development. Based in Tel Aviv, Israel and founded in 2025, Undecimal Bio provides RNA delivery technology for therapeutic development. The company was co-founded by Yaniv Erlich (CEO) and Shaul Ilan. In October 2026, Undecimal Bio raised USD 18 million in seed funding co-led by investors 4BIO Capital Partners, and IQ Capital, with participation from other investors Verve Ventures, Harel Insurance, Entree Capital, Kerna Ventures, and Saras Capital.


Undecimal Bio specializes in AI-driven delivery systems for small interfering RNA (siRNA) therapeutics, utilizing combinatorial chemistry and transformer-based AI capabilities. Their offerings focus on targeting specific tissues, particularly in the kidney and vascular system, where traditional delivery methods are inadequate. The company systematically evaluates numerous delivery candidates to identify molecules that facilitate effective intracellular delivery, addressing unmet medical needs in treating renovascular diseases. Their primary customers include pharmaceutical companies and investors interested in RNA medicine.


Undecimal Bio operates on a revenue model that incorporates partnerships and collaborations with pharmaceutical companies. These partnerships may involve revenue-sharing agreements for co-development and commercialization of siRNA delivery products, often structured as contractual partnerships with upfront fees and milestone payments. The company’s revenue dynamics are influenced by its commitment to developing effective delivery mechanisms for siRNA-based therapies, establishing a pipeline approach to product development. The company will use the October 2026 funding to advance its delivery molecule and therapeutic siRNA platform, continue testing in primary human cells, and expand its UK team.


Current Investors

Harel Insurance, IQ Capital, Entree Capital, 4BIO Capital Partners, Verve Ventures, Saras Capital, Kerna Ventures

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development

Website

www.undecimalbio.com

Verticals

Artificial Intelligence, HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Undecimal Bio - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
SeedCompletedUndecimal Bio-

Displaying 1 - 1 of 1

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.